TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group, Inc.

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

United States Lung Revenue

United States Lung Revenue % Chg.

United States Lung Revenue Common Size

United States Heart Revenue

United States Heart Revenue % Chg.

United States Heart Revenue Common Size

United States Liver Revenue

United States Liver Revenue % Chg.

United States Liver Revenue Common Size

United States OCS Transplant Revenue

United States OCS Transplant Revenue % Chg.

United States OCS Transplant Revenue Common Size

All Other Countries Lung Revenue

All Other Countries Lung Revenue % Chg.

All Other Countries Lung Revenue Common Size

All Other Countries Heart Revenue

All Other Countries Heart Revenue % Chg.

All Other Countries Heart Revenue Common Size

All Other Countries Liver Revenue

All Other Countries Liver Revenue % Chg.

All Other Countries Liver Revenue Common Size

All Other Countries OCS Transplant Revenue

All Other Countries OCS Transplant Revenue % Chg.

All Other Countries OCS Transplant Revenue Common Size

Total OCS Transplant Revenue

Total OCS Transplant Revenue % Chg.

Total OCS Transplant Revenue Common Size

Other Service Revenue

Other Service Revenue % Chg.

Other Service Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Net Product Revenue

Net Product Revenue % Chg.

Net Product Revenue Common Size

Service Revenue

Service Revenue % Chg.

Service Revenue Common Size

Revenue	LTM	Dec '24	Dec '23
United States Lung Revenue	14.6	15.8	10.5
United States Heart Revenue	110.6	96.7	59.1
United States Liver Revenue	421.3	309.5	151.7
United States OCS Transplant Revenue	546.5	421.9	221.3
All Other Countries Lung Revenue	1.5	1.9	1.3
All Other Countries Heart Revenue	13.6	13.2	14
All Other Countries Liver Revenue	0.6	0.2	0.1
All Other Countries OCS Transplant Revenue	15.7	15.3	15.4
Total OCS Transplant Revenue	563	437.2	236.7
Other Service Revenue	—	4.4	4.9
Total Revenue	566.4	441.5	241.6

Revenue	LTM	Dec '24	Dec '23
Net Product Revenue	347	273.9	176.1
Service Revenue	219.4	167.7	65.6
Total Revenue	566.4	441.5	241.6